The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback